Advances in Adjuvant Therapy for High-Risk Breast Cancer: A Canadian Clinical Approach
Canadian Oncology Today · 2025
DOI: 10.58931/cot.2025.2134 ↗Kurz gefasst
Fachartikel in der Zeitschrift Canadian Oncology Today, 2025. Verfasst von Samitha Andrahennadi und 1 weiteren Autor:innen. Die Arbeit nennt 26 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).
Abstract (Originalsprache)
Breast cancer remains the second leading cause of cancer-related death among women in Canada. In early-stage disease, the purpose of adjuvant therapies following surgical resection is to reduce the risk of recurrence. The advent of adjuvant endocrine therapy (ET) significantly reduced breast cancer recurrence and mortality; however, some patients have disease recurrence even 20 years after initial diagnosis. Therefore, several advancements have been made to optimize cure rates and improve outcomes. As a heterogeneous disease, breast cancer outcomes are impacted by clinical, histological, and genomic features, which guide prognosis and selection of adjuvant therapy. This review focuses on recent and emerging adjuvant therapies, specifically for high-risk patients across breast cancer subtypes: hormone receptor‑positive (HR‑positive), human epidermal growth factor receptor 2-positive (HER2-positive), and triple‑negative breast cancer (TNBC).
Zitieren
APA
Andrahennadi, S., & Manna, M. (2025). Advances in Adjuvant Therapy for High-Risk Breast Cancer: A Canadian Clinical Approach. Canadian Oncology Today. https://doi.org/10.58931/cot.2025.2134
Vancouver
Andrahennadi S, Manna M. Advances in Adjuvant Therapy for High-Risk Breast Cancer: A Canadian Clinical Approach. Canadian Oncology Today. 2025. doi:10.58931/cot.2025.2134
BibTeX
@article{Andrahennadi2025,
author = {Andrahennadi, Samitha and Manna, Mita},
title = {Advances in Adjuvant Therapy for High-Risk Breast Cancer: A Canadian Clinical Approach},
journal = {Canadian Oncology Today},
year = {2025},
doi = {10.58931/cot.2025.2134}
}
EUVIMED